PTC Therapeutics Inc (PTCT)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $5.09B
Last updated: Nov 17, 2026 at 4:20 PM ET
PTC Therapeutics Inc (PTCT) Stock Chart
PTC Therapeutics (PTCT) has a latest price of $60.36 on Nov 17, 2026, 33.6% below its 52-week high of $90.87. Its price fell 19.8% over the past 12 months. The month-end price rose 865.7% over the 10 years through Oct 2026, a compound annual rate of 25.5%.
Price Chart
From Oct 2016 to Oct 2026, its highest month-end close was $85.99 in Nov 2025 and its lowest $6.21 in Oct 2016, adjusted for splits.
Month-end closes, adjusted for splits. Dividends are not included.
Chart PTCT with Advanced Charting
Daily candlesticks, valuation multiples, side-by-side comparisons and drawings for PTCT.
Free with a GNG account. No credit card.
Price Performance
Over the past 3 months the price fell 18.1%, and over 6 months it fell 14.2%. The month-end price rose 219.8% over the 3 years through Oct 2026, a compound annual rate of 47.3%.
| Period | Change |
|---|---|
| 1 month | -1.9% |
| 3 months | -18.1% |
| 6 months | -14.2% |
| 12 months | -19.8% |
| 12 months, with dividends | -19.8% |
| Period | Change | Per year |
|---|---|---|
| 3 years | +219.8% | +47.3% |
| 5 years | +58.1% | +9.6% |
| 10 years | +865.7% | +25.5% |
Price by Year
Its best calendar year was 2018, when the price rose 105.8%, and its weakest was 2021, when it fell 34.7%.
| Year | Close | Change |
|---|---|---|
| 2026 through Oct 2026 | $59.97 | -21.1% |
| 2025 | $75.96 | +68.3% |
| 2024 | $45.14 | +63.8% |
| 2023 | $27.56 | -27.8% |
| 2022 | $38.17 | -4.2% |
| 2021 | $39.83 | -34.7% |
| 2020 | $61.03 | +27.1% |
| 2019 | $48.03 | +39.9% |
| 2018 | $34.32 | +105.8% |
| 2017 | $16.68 | +52.9% |
Trading Range
The price is 5.4% below its 50-day average of $63.78 and 13.8% below its 200-day average of $70.02.
| Measure | Value | Price vs |
|---|---|---|
| Latest price (Nov 17, 2026) | $60.36 | |
| 52-week high | $90.87 | -33.6% |
| 52-week low | $58.80 | +2.7% |
| 50-day average | $63.78 | -5.4% |
| 200-day average | $70.02 | -13.8% |
Price Risk
Over 3 years, its largest fall from a peak was 36.7%.
| Measure | Value |
|---|---|
| 1-year beta | 0.86 |
| Largest fall, 1 year | -33.8% |
| Largest fall, 3 years | -36.7% |
Advanced Charting Features
Advanced Charting is free with a GNG account, and signed-in members get it in place of the price chart above.
- Valuation multiples. Daily P/E, price to sales, cash flow and book value, PEG and PEGY, drawn behind the price wherever the company's data supports them.
- Price charts and drawings. Candlestick, OHLC, line and area charts with volume and earnings, dividend and split markers, plus trend lines, levels and notes kept in your account.
- Side-by-side compare. Two stocks next to each other on one metric and time span, each chart with its own price scale.
- Projections and saved views. Pick a start and an end point to see the price return, dividends and total return between them, and save views to open later.
Frequently Asked Questions About PTCT
What is PTCT's 1-year price change?
PTC Therapeutics's price fell 19.8% over the past 12 months. With dividends included, the 12-month total return was -19.8%.
What is PTCT's 5-year price change?
PTC Therapeutics's month-end price rose 58.1% over the 5 years through Oct 2026, a compound annual rate of 9.6%. These figures leave out dividends.
What is PTCT's 52-week high and low?
PTC Therapeutics's 52-week high is $90.87 and its 52-week low is $58.80. Its latest price of $60.36 on Nov 17, 2026 is 33.6% below the high.
What is PTCT's beta?
PTC Therapeutics's 1-year beta against the S&P 500 is 0.86, so its price has moved about in line with the market over the past year. Its largest fall from a peak over the past year was 33.8%.
Is the PTCT chart free?
Yes. Advanced Charting for PTCT is free with a GNG account, and no credit card is needed. It adds daily candlestick and line charts with volume, valuation multiples, side-by-side comparisons, drawings and saved views.
PTCT pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors